Login to Your Account

Investors Step Up for PTC's $30M Round for DMD Trials

By Catherine Shaffer
Staff Writer

Wednesday, August 8, 2012

Following encouraging results from a Phase III trial, PTC Therapeutics Inc., of South Plainfield, N.J., completed a $30 million financing to support late-stage development of ataluren. The drug has showed clinically meaningful trends in Duchenne's and Becker muscular dystrophy and cystic fibrosis.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription